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Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low
among individuals with SCD. The objective of this study was to examine barriers to patients’
adherence to hydroxyurea use regimens by using the intentional and unintentional
medication nonadherence framework. We interviewed individuals with SCD age 15 to
49.9 years who were participants in the Sickle Cell Disease Implementation Consortium
(SCDIC) Needs Assessment. The intentional and unintentional medication nonadherence
framework explains barriers to using hydroxyurea and adds granularity to the
understanding of medication adherence barriers unique to the SCD population. In total,
90 semi-structured interviews were completed across 5 of the 8 SCDIC sites. Among
interviewed participants, 57.8% (n5 52) were currently taking hydroxyurea, 28.9% (n5 26)
were former hydroxyurea users at the time of the interview, and 13.3% (n 5 12) had never
used hydroxyurea but were familiar with the medication. Using a constructivist grounded
theory approach, we discovered important themes that contributed to nonadherence to
hydroxyurea, which were categorized under unintentional (eg, Forgetfulness, External
Influencers) and intentional (Negative Perceptions of Hydroxyurea, Aversion to Taking Any
Medications) nonadherence types. Participants more frequently endorsed adherence
barriers that fell into the unintentional nonadherence type (70%) vs intentional
nonadherence type (30%). Results from this study will help SCD health care providers
understand patient choices and decisions as being either unintentional or intentional, guide
tailored clinical discussions regarding hydroxyurea therapy, and develop specific, more
nuanced interventions to address nonadherence factors.
Introduction
Sickle cell disease (SCD) is the most prevalent genetic condition worldwide with estimates of around
300000 births of patients with SCD each year.1,2 In the United States,;100000 people are living with
the disease.3 The majority of cases in the United States are among African Americans and Hispanic/
Latinx Americans, which impacts 1 of 365 births to African American parents and 1 of 16 300 births to
Hispanic-American parents.1,3 In 1998, the US Food and Drug Administration approved hydroxyurea for
use in SCD after a pivotal clinical trial which showed that hydroxyurea reduced the frequency of pain
Submitted 19 February 2020; accepted 28 July 2020; published online 17 September
2020. DOI 10.1182/bloodadvances.2020001701.
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events by .40%.4,5 Subsequent trials continued to demon-
strate the role of hydroxyurea in the reduction of pain crises6 and
mortality rates and the improvement in quality of life for people
living with SCD.7 Despite these positive outcomes, hydroxyurea
remains underused by patients8,9 and providers.10 Poor adherence
to hydroxyurea regimens contributes to greater use of health care,
lower self-reported quality of life, and higher health care costs.11-13
Studies that seek to explain and intervene upon this underuse of
hydroxyurea among patients are increasing; however, compared
with studies of treatments used in other chronic diseases, studies
that use various theories of adherence to treatments in SCD
are underrepresented.14 It is important to test and investigate
theoretical frameworks for understanding and intervening upon
adherence to treatment in SCD because of the complexity of the
disease’s impact over the lifespan, the sociodemographic charac-
teristics of those living with SCD, and how these factors are
intertwined in adherence behaviors.15
Understanding the complexity of adherence and developing
interventions that aim to have an impact on adherence calls for
a framework that considers the intentionality of nonadherence.
Intentional nonadherence and unintentional nonadherence expand
on the concept of adherence, moving from a simplistic binary
construct (adherent vs nonadherent), by which the patient exerts
little agency or control in medical decision-making and behavior, to
a richer and more nuanced view of adherence, acknowledging the
patient’s (and medical team’s) active and passive roles throughout
the medical care continuum.16 Intentional nonadherence positions
patients as actors who have agency in making rational decisions
to adhere, modify, or disregard treatment advice from medical
professionals.16 Factors that underlying their decisions vary from
experiencing adverse effects17 to their perceptions of the need
for the prescribed treatment.18 The concept of intentionality has
been used to examine treatment nonadherence among individuals living
with a variety of chronic conditions, including coronary heart
disease,19-21 glaucoma,22 kidney disease,23 hypertension,20,24
epilepsy,25 and diabetes.21,24 This research has led to tailored
interventions, with mixed results, and recommendations that focus
on intentional and unintentional nonadherence.24,26-30 In addition to
understanding the nuances of adherence types, it is important to
understand the phases within the adherence process provided by
the Components of Adherence concept. The Components of
Adherence concept assigns barriers to adherence to specific
phases of an individual’s adherence decision-making process:
Initiation, Discontinuation, and Implementation.24 Initiation pertains
to the processes involved in an individual’s decision to start taking
hydroxyurea. Discontinuation is the phase in which an individual
decides to discontinue taking hydroxyurea. Implementation encom-
passes those activities that concern everyday adherence to taking
hydroxyurea. Adherence in this sense refers to taking hydroxyurea
as prescribed and directed by the individual’s medical team.
The concepts of intentional nonadherence and unintentional
nonadherence are not currently found in the SCD adherence
literature. This gap contributes to an understatement in the literature
regarding the complexity of making decisions regarding adhering
or not adhering to a hydroxyurea regimen by focusing primarily on
individual-level factors and neglecting external influencers. Fac-
tors related to the unintentional nonadherence category can be
interpreted as those that are not as closely linked to an individual’s
attitudes or beliefs.16 Underlying contributors to unintentional
nonadherence include misunderstanding of medical instruc-
tions, the burden of complex treatment regimens, never being
offered the drug, being removed from a regimen because of the
medical team’s decision, and the quality and strength of the
patient-provider relationship.16 These categories of nonadher-
ence could play an important role in helping care providers more
fully understand adherence behaviors among people with SCD,
especially given the demonstrated mistrust of medical providers
and the medical establishment overall, including the perceived
lack of agency in this power dynamic,31,32 evidence of low
health literacy among people living with SCD,33 and beliefs
about the efficacy and safety of hydroxyurea.34,35
The purpose of this article is to add to the literature on hydroxyurea
adherence by exploring, via qualitative methodology, the uninten-
tional and intentional nonadherence factors that influence adher-
ence decisions among individuals with SCD who participated in
a multicenter study and who represented a diverse geographic
distribution in the United States.
Methods
Participant recruitment
Participants for in-depth interviews were recruited at 5 academic
centers that participated in the qualitative portion of the Sickle Cell
Disease Implementation Consortium (SCDIC) Needs Assessment.
The SCDIC represents academic and medical centers across the
United States that use implementation science to improve
the health and well-being of individuals living with SCD.15 The
purpose of the SCDIC Needs Assessment study was to identify
barriers to hydroxyurea adherence and use, transitioning to adult
care, emergency department care, and engagement in routine
care.15,21 All individuals with a diagnosis of SCD between age 15
and 49.9 years were eligible to participate. Purposive sampling
was used to identify potential participants at each site and obtain
a sample that varied in terms of age, sex, disease complexity,
history of SCD, current affiliation with a sickle cell provider, and
rural vs urban residence.
Ethical considerations
Study sites obtained institutional review board approval before
study startup. Trained study staff reviewed the overall study with
participants; for participants age 18 years or older, they obtained
signed written informed consent. Assent was obtained from
participants age 15 to 17 years, with consent obtained from the
parent or primary caregiver.
Data collection
Data from the SCDIC Needs Assessment were collected from
2017 to 2018.36 An interview guide was developed by an SCDIC
subcommittee of consortium members who had qualitative research
expertise and extensive experience working with individuals with SCD
(supplemental Data). Subcommittee members met virtually twice
per month to discuss and develop open-ended questions and probes
to be included on the interview guides. Draft interview guides were
circulated and revised by subcommittee members until consensus
was reached on the draft of the interview guide. The interview guide
was then voted on and approved by the SCDIC Steering Committee
before being used. Data in this study are from the hydroxyurea use
section of the interview guide. Participants were recruited by trained
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research staff during clinic visits and SCD-related community events.
Interviews were conducted by trained qualitative researchers, and
they lasted 45 to 75 minutes. Interviews were audio recorded and
transcribed verbatim. Interview participants also completed a de-
mographic survey. Participants were compensated for participating in
the interview.
Data analysis
Interview transcripts were redacted for identifiable information,
reviewed for accuracy, and uploaded into Dedoose Version 7.0.23
(SocioCultural Research Consultants, Los Angeles, CA) for
qualitative analysis. This platform allowed the authors to collaborate
in real-time during coding and analysis. Using real-time software
solved the problem of authors not being physically located in the
same space and allowed for constant collaboration throughout the
data analysis process. Twice-per-month meetings occurred via
WebEx (Cisco) to discuss study topics, address challenges with
using the qualitative analysis software, and facilitate cross-site
collaboration.
Charmaz’s constructivist grounded theory (CGT) guided the
analytic approach. This analytic approach was ideal for this
study because it focused on being immersed in the data and at
the same time acknowledging the role of the researchers as
coproducers in the analytic process.37 The authors followed
a 2-phase, cyclical coding process that included initial (or open
coding) and focused coding (Figure 1).38 Larger thematic concepts
were then developed by holistically combining codes to un-
derstand how they contributed to the larger meaning making of
the participants.
A subset of transcripts was coded by 2 independent coders using
the initial code to examine agreement of codes using interrater
reliability scores in Dedoose via Cohen’s k coefficient with a score
of 0.877. In addition, all coders met twice per month during each
phase of the coding process to refine the codebook and resolve
any discrepancies until a consensus was reached among the team
members. Once thematic saturation was reached (ie, no new
codes or themes were being discovered), themes (as defined by
clustering of similar codes) were developed, categorized, and
assigned to their respective cell within the Adherence Type (ie,
Intentional and Unintentional) and Components of Adherence
matrix (Table 1). 12,24,39The text and codes were queried to
explore the frequency and distribution of thematic codes by
participants’ demographic characteristics. Examples include the
frequency of codes for adherence barriers among male and female
participants, age groups, or those exposed to hydroxyurea in the
past, as well as how larger themes were distributed within smaller
groups such as former and current hydroxyurea users. This
checking provided assurance that the theories derived from the
data properly identified divergences among subgroups when or if
they existed.
Results
Ninety participants completed in-depth interviews from SCDIC
sites located in Illinois, North Carolina, South Carolina, Tennes-
see, and California. Females represented 57% of participants
with a mean age of 30.5 years (standard deviation, 8.7 years).
Table 2 provides the distribution of demographic characteristics
of interview participants. Most participants (87%) had taken
hydroxyurea at some point in their lives, and 67% reported that
they were taking hydroxyurea at the time of the interview. Of the
participants who had taken hydroxyurea but were not currently
taking it at the time of the interview, 14 types of barriers were
identified; of those, 64.3% of the barriers (9) fell into the unintentional
nonadherence category. Among those currently taking hydroxyurea,
75.7% of the barriers were considered unintentional nonadherence
barriers. For the 87% of participants with any history of hydroxyurea
use, approximately 69.9% endorsed unintentional barriers (Table 1).
Five participants endorsed barriers that fell into both unintentional and
intentional categories; in these cases, the coded barrier was counted
for each category.
Initiation
A majority of the 12 participants who had never taken hydroxyurea
(n 5 7) endorsed initiation barriers categorized as unintentional
nonadherence. These participants discussed never being offered
hydroxyurea by their doctor as the primary reason for never taking
hydroxyurea. This could be attributed to the participants’ percep-
tions that their genotype was less severe than other genotypes,
thereby making it less likely that a physician would determine a need for
a hydroxyurea regimen.40 Themes within the intentional nonadherence
barriers categories were less frequently observed compared with
unintentional nonadherence barrier themes.
Unintentional nonadherence. Among participants who never
started hydroxyurea, the primary codes in this category were a lack of
discussion with health care providers about hydroxyurea and no
prescription recommendation for hydroxyurea. These codes were
somewhat varied across age groups with younger participants noting
a lack of awareness or initial discussion about hydroxyurea from their
experiences.
Well, I don’t really know what it is. I’m not sure if I’ve ever been
offered to take it, just as far as my medical history goes. I’m not
sure if my mom or anything has ever been offered it, but as far
as I know, I’ve never had to take it. (18-year-old female)
Older participants were somewhat more familiar with hydroxyurea
yet described no formal discussion with their providers about
starting the treatment regimen. “I’ve heard some talks about it, but I
haven’t heard about ‘are you interested in trying it as of yet’” (32-
year-old female).
Intentional nonadherence. Among participants endorsing an
intentional barrier to starting hydroxyurea, most pointed to fears
about potential adverse effects (including a fear of cancer),
witnessing a friend or family member either not benefiting from
hydroxyurea or experiencing unwanted adverse effects, and being
generally against taking more medications.
There’s a friend of mine. Well not of mine, my dad’s friend, that
takes it, and he had the negative side effects that I heard about
it happen to him. He wasn’t the same after he took it, meaning
appearance-wise. And so, it kind of scared me into not taking it.
(17-year-old female)
[…] the side effects that I heard were cancer, that it can cause
cancer, and let’s see, I heard about the falling out of the hair
and the nail beds getting yellower or yellow or something.
Those didn’t – the main thing that made me not heed [the
doctor’s] recommendations of taking it or that previous
physician’s recommendations of taking it was the cancer fear,
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the fear of like look, I already have sickle cell, I don’t need
anything else. I just wasn’t convinced. That physician wasn’t
convincing [me] that it would be something that would be
worth the risk. (45-year-old male)
Implementation
Most participants identified implementation barriers that could
be categorized as unintentional nonadherence. Fifty-two partic-
ipants were taking hydroxyurea at the time of the interview; of
these 52, only 15% (n 5 8) mentioned intentional barriers to
adherence. Interestingly, almost half this group (n 5 25), stated
they experienced no barriers to adherence with hydroxyurea
maintenance (ie, implementation phase).
Uunintentional nonadherence. The overwhelming majority of
unintentional barriers within the implementation phase fell into the
theme of Forgetting to Take Hydroxyurea. Codes grouped under
this theme included Competing Life Demands and Forgetting to
Take Hydroxyurea With Them When Not at Home.
The theme of Forgetting to Take Hydroxyurea seemed to be
prevalent across all age groups; only the Competing Life
Demands code differed by age group. For example, one 15-
year-old male stated, “Sometimes I forget or we’re out of it.
That’s the only time. But, it’s not like I don’t feel like it or anything.
Sometimes I just forget, if I’m watching TV or playing a game.”
Others pointed to the complexity of a multiple-drug regimen as
a factor contributing to Forgetting to Take Hydroxyurea:
I have so many meds that I have to take. Like I have I want to say
14 to 18 meds that I have to take a day, and Hydroxyurea’s the
one that I be like okay I’m taking this at night, set schedule, take
it. I even have like the little planner with the days on it, I have
that. So just remembering to take my medicine, all my meds
that I have is the barrier that I have with taking my meds. (22-
year-old female)
Intentional nonadherence. Intentional barriers to implementa-
tion were less frequently endorsed among participants. The themes
within this category included Does Not Like Taking Any Medication,
Uncertainty of Hydroxyurea’s Effectiveness, and Perception Hydroxy-
urea Was Causing More Negative SCD-Related Outcomes. Of these
themes, the most commonly cited intentional barrier to implementation
of hydroxyurea was a general dislike of taking any medication. One 32-
year-old male explained this aversion, “I don’t like taking pills. It was,
there was no barrier [to adherence]. I could do it, it’s just that I didn’t
want to.” Others pointed to subjective interpretations of whether or
not hydroxyurea truly needed to be taken on a daily basis, particularly if
one is not experiencing any negative SCD-related outcomes or has
not experienced a crisis in a long period of time:
For a while I was taking it pretty consistently, now like I will










Coding Process using Constructivist Grounded Theory1
Initial Coding Phase:
• Line-by-line gerund coding
 “forgetting to take”
 “experiencing side effects”
• Checked for inter-rater reliability
 Discussed discrepancies w/
      team
Review Themes and Codes
• Ensured no codes were
  unassigned to thematic
  categories
• Discussed any discrepancies
  until consensus was reached
• Reviewed distribution of
  themes by demographics
Adopted from:
1.  Charmaz K.Constructing grounded theory.2nd edition ed. London
     Thousand Oaks, Calif.: Sage; 2014.
Focused Coding Phase
  • Reviewed similar codes
  • Discussed discrepancies and
    meanings of codes
  • Memoed emerging themes
  • Discussed with team
Identification of Themes
  • Aligned prominent codes
    under larger thematic areas
    (e.g., Intentional or
    Unintentional
    nonadherence)
  • Discussed thematic
    categories
Figure 1. Coding process using constructivist grounded theory. Adapted from Charmaz.38
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its head a little bit, but I mostly don’t take it, and I’m being like so
real. [Laughs] (20-year-old female)
Discontinuation
Participants were considered a part of the Discontinuation phase if
they ever stopped taking hydroxyurea in the past and were not taking
it at the time of the interview. Twenty-nine percent (n 5 26) of
interview participants experienced the discontinuation phase. Partic-
ipants were asked to provide their reasoning behind this decision.
Unintentional nonadherence Similar to barriers found within
the initiation phase, the majority of participants that discontinued
hydroxyurea (n 5 21 [81%]), endorsed factors leading to discontin-
uation that were categorized as unintentional. The most prominent









Initiation Decided not to start Negative attitudes or perceptions of hydroxyurea 5 External influencers 11
Fear of adverse effects 4 Doctor did not prescribe hydroxyurea 7
Does not like taking medication in general 1 Witnessed hydroxyurea not helping others 3
Uncertainty of potential effectiveness 2 Caregiver made decision to not start 1
Implementation Adherence while taking Does not like taking medicines in general 6 Forgetfulness 22
Did not perceive any benefits, contributing to lack
of motivation to take regularly
2 Competing life demands 3
Complexity of treatment regimen (eg, multiple
medications, different dosages, multiple pills)
6
Taking hydroxyurea with food; forgetting or not
getting a chance to eat so misses dose
1
Physical and emotional state on any day 1
Logistics of obtaining hydroxyurea (laboratory
visits, pharmacy trips)
1
Discontinuation Decision to discontinue
taking
Grew concerned about hydroxyurea because of
potential adverse effects, history of hydroxyurea
as a cancer drug, preference for treatments
other than hydroxyurea (eg, chronic
transfusions), did not perceive hydroxyurea as
being effective
8 Experienced adverse effects 16
3 Hydroxyurea was not effective per medical team
report
10
5 Taken off hydroxyurea because of poor adherence 1
5 Pregnancy 3
4 Medical team decision 7
Table 2. Demographic characteristics for interview participants according to hydroxyurea use
Current users
(n 5 52 [57.8%])
Never users
(n 5 12 [13.3%])
Former users
(n 5 26 [28.9%]) All (N 5 90 [100%])
No. % No. % No. % No. %
Age group, y
15-24.9 19 3.8 4 16.6 3 3.8 26 28.9
25-34.9 17 32.7 4 33.3 12 46.1 33 36.7
35-49.9 16 30.7 4 33.3 11 42.3 31 34.4
Sex
Female 26 50.0 8 66.6 17 65.4 51 56.7
Male 26 50.0 4 33.3 9 34.6 39 43.3
Enrollment site
Chicago 6 11.5 1 8.3 3 11.5 10 11.1
Duke University 7 13.5 — — 3 11.5 10 11.1
Medical University of South Carolina 9 17.3 3 25.0 3 11.5 15 16.7
St. Jude Children’s Research Hospital 13 25.0 5 41.7 2 7.7 20 22.2
University of California San Francisco 17 32.7 3 25.0 15 57.7 35 38.9
Mean age (SD), y 29.61 (8.2) 28.96 (11.2) 33.07 (8.25) 30.5 (8.7)
SD, standard deviation.
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themes within this category included Medical Team Decision (because
of the lack of a clinical response), Taken off Hydroxyurea by Medical
Team Due to Poor Adherence, Pregnancy, and Experience of Side
Effects. The experience of adverse effects varied from leg ulcers to
hair loss.
I mean, I know in other situations that some people may not
experience it, but in my particular case I did have a leg ulcer as
an effect of hydroxyurea, but I will say is that the hydroxyurea
did help me as far as my crisis. It kept me from being in crisis
a lot more than I was prior to taking it. But the side effect of
that was I developed a leg ulcer, and that in itself was
probably more excruciating than any crisis I’ve ever been in.
(34-year-old male)
A less commonly vocalized reason for being taken off hydroxyurea
was an adverse reaction identified by the medical team. As one 26-
year-old female described, “I was having some issues with like my
platelet count and [my doctor] wanted me to stop taking it for
a while to see if it made any changes to it.”
Intentional nonadherence. The remaining participants de-
scribed intentional nonadherence that were categorized into the
following themes: Changing Attitudes/Perceptions About the
Safety of Hydroxyurea, Perceptions that Hydroxyurea Was Not
Effective (without a medical team endorsement of this statement),
and Chronic Transfusion as a Preferred Method of SCD Management.
No definitive pattern of these themes was observed across de-
mographic groups. The most common codes for this section, Changing
Attitudes About Hydroxyurea, seemed to occur after the patient
conducted research on his or her own or had a personal experience that
changed his or her perceptions of its safety. The changing perception of
hydroxyurea as a safe drug influencing the decision to discontinue is
exemplified below.
Honestly, I just didn’t trust [hydroxyurea]. If I can’t touch this
with my hands and I have to bypass my tongue, but it’s being
ingested into my body, that’s–something about that doesn’t
sound right, you know? (28-year-old female)
Medical team member’s precautions for the physical handling of the
hydroxyurea pill was also viewed as concerning and caused some
participants to become cautious about the drug’s overall safety and
whether or not it was, in fact, harmful:
And you notice how they give [hydroxyurea] to you [as an]
inpatient at the hospital, the nurses don’t even touch it; they put
gloves on, they say don’t touch it. And then from two years ago
to now I’ve just been full of questions like well why is it okay for
me to take it they can’t even touch it? And finally, about
a month ago I looked it up and I saw that it depletes bone
marrow. And then that’s when I was like, ‘oh. I’m not taking it
anymore’. So that, I’ve been off of it since then. (32-year-old
female)
Notably, a few participants described a preference for chronic red
cell transfusion therapy (chronic transfusion) over hydroxyurea for
disease management. The reasoning included the perception that
chronic transfusion had a better perceived effect than hydroxyurea,
combined with participants’ negative attitudes about medications in
general.
I don’t like doing blood transfusions either, but I’ve decided not
to take the pills because I’ve tried taking or doing the pills first,
and the pills do not keep me feeling as good as transfusions do.
(45-year-old male)
Discussion
Whether in the initiation, implementation, or discontinuation phase
of hydroxyurea therapy, more individuals with SCD who participated
in this study described barriers leading to unintentional non-
adherence (70%) than intentional nonadherence (30%), suggest-
ing the majority of barriers to adherence are not the result of
conscious decision-making on the part of the patient. Participants in
the initiation phase most commonly stated that they never started
taking hydroxyurea because it was not introduced by their provider;
similarly, in previous studies, individuals with SCD reported
never beginning hydroxyurea therapy because it was not
recommended by their provider.31,41 Reasons that hydroxyurea
may have not been introduced include provider barriers such as
a lack of awareness leading to underprescribing,42providers’
beliefs about a patient’s likelihood to be adherent,9 or providers
with experience and knowledge making decisions that included
consideration of a patient’s clinical characteristics.43 Among partic-
ipants in the implementation phase (those currently receiving
hydroxyurea therapy), the most common barrier leading to un-
intentional nonadherence was forgetting to take hydroxyurea,
a key barrier that has been well recognized and described in
the literature.44-48 Participants reported facing competing life
demands, also described by Thornburg and colleagues,49 which
contributed to forgetting to take hydroxyurea. More than 80% of
participants in the discontinuation phase mentioned stopping
hydroxyurea because their health care team recommended it.
This finding is similar to a report by Haywood et al41 in adults
with SCD who were formerly taking hydroxyurea and stopped
taking it. Their primary reason was a doctor’s recommendation.
Among participants who reported barriers leading to intentional
nonadherence, a general dislike of taking medications was
described by participants in all 3 phases. In addition to a general
dislike of taking medications, some participants in the initiation
phase described never starting hydroxyurea because of a fear of
adverse effects. A fear that hydroxyurea is not safe and that it
has adverse effects are well-known barriers to hydroxyurea
adherence,31,44 along with negative beliefs about the medica-
tion (eg, that hydroxyurea is not effective).22,44,46
Participants in this study who were in the implementation phase
described negative beliefs as a barrier that contributed to intentional
nonadherence. Few participants in the discontinuation phase
described barriers leading to intentional nonadherence; however,
the majority described their changing attitudes and beliefs about
hydroxyurea as the primary reason for discontinuation. This finding
is similar to findings reported by Badawy et al22 that among
adolescents and young adults with SCD, increased concerns about
hydroxyurea were associated with decreased adherence. A small
percentage of individuals with intentional nonadherence in the
discontinuation phase described preferring chronic red cell trans-
fusion to hydroxyurea as a disease-modifying therapy, a finding not
described previously in the literature on barriers to hydroxyurea
adherence. Given the time and resource commitment required by
patients for chronic red cell transfusion therapy, the preference for
chronic red cell transfusion over hydroxyurea suggests either a high
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level of negative perceptions or experiences with hydroxyurea or
a higher perceived benefit of chronic red cell transfusion therapy by
patients electing to discontinue hydroxyurea in favor of chronic red
cell transfusion therapy.
In this study, half the participants in the implementation phase
reported no barriers to taking hydroxyurea. Previous reports
indicated that ;90% of parents or caregivers of children with
SCD endorsed barriers to hydroxyurea therapy for their children45;
a substantially lower number of participants in this study identified
barriers to hydroxyurea therapy. This could be attributed to sample
differences in this study. For example, the population in this study
may be more adherent, as determined by more objective measures.
Because the purpose of this study was to explore perceived barriers
that contributed to intentional and unintentional nonadherence,
data were not collected on participants’ actual or self-reported
adherence rates.
Thus, the relationship between number of (or lack of) perceived
barriers and adherence rates was not explored. However, previous
studies have reported that greater numbers of barriers are
associated with lower adherence rates.21,42,44,46 Future studies
may be beneficial in better understanding whether individuals with
SCD or caregivers who perceive no barriers to hydroxyurea
adherence do, in fact, have higher adherence rates.
Barriers to hydroxyurea adherence from the perspectives of
children with SCD and their parents and caregivers or adolescents
and young adults with SCD have been more commonly reported
than barriers from the perspective of adults with SCD. Although
many of the barriers reported by participants in this study have been
described previously in the literature, this study introduces the role
of patient agency or power in nonadherence by examining barriers
leading to intentional and unintentional nonadherence among those
who have never taken hydroxyurea, those currently receiving
hydroxyurea therapy, and those who have discontinued hydroxyurea
therapy. This deeper understanding of barriers to hydroxyurea
adherence can be applied in the clinical setting to inform treatment
strategies specific to a patient’s phase (initiation, implementation, or
discontinuation) and intentional vs unintentional nonadherence
barriers. Table 3 outlines examples of strategies that may be applied
in each phase to address intentional or unintentional nonadherence
within the phases of adherence. As seen in Table 4, several
strategies to address adherence barriers may have an impact on
various types of adherence. These cross-influencing strategies
might be prime candidates for testing in more rigorous interven-
tional studies.
In 2013, a National Institutes of Health Consensus Statement
on hydroxyurea treatment of SCD identified only 3 studies that
addressed barriers to hydroxyurea, none of which tested interven-
tions.50 Currently, the majority of interventions that address barriers to
hydroxyurea adherence are designed for children or adolescents and
young adults and have undergone pilot testing but have not reported
testing via adequately powered randomized control trials.44,51-54
Importantly, the SCDIC is currently testing a mobile health (mHealth)
intervention designed to address the major unintentional barrier:
forgetting to take the drug.55,56 Findings from our qualitative
study may be used in future research through development and
testing of multimodal interventions for adults with SCD to
improve initiation of hydroxyurea or adherence to hydroxyurea by
including the role of patient agency and specifically addressing
barriers leading to intentional or unintentional nonadherence.
Limitations
An important limitation of this study is the lack of data captured to
assess the current adherence status of participants; however, these
interview participants represent a subsample of the SCDIC
registry,57 wherein 42.1% of respondents (n 5 462) self-reported
poor adherence. Limited collection of sociodemographic character-
istics was also a limitation to understanding how these variables
could impact adherence decisions. Future studies should in-
corporate these variables into the study design to assess their
impact on adherence.
In addition, the aim of this study was to explore barriers from the
perspective of individuals living with SCD to provide rich
descriptions of barriers and introduce new variables relevant to
hydroxyurea adherence to test in future studies. Study participants
in this sample were recruited via purposive sampling at SCD clinics,
health fairs, and SCD advocacy groups. Although attempts were
made to identify which individuals were currently engaged in care
and which were not, the sampling approach led to challenges in
identifying individuals not currently engaged in care, an important
subgroup of patients with SCD. Given the number of sites, there
was some variation in conducting the qualitative research study. For
example, sites were not required to conduct all topical areas in the
semi-structured interview guide; however, the hydroxyurea use and
barriers section was required by all sites participating in the
qualitative component of the Needs Assessment. To address these
concerns, all sites were trained before collecting data to ensure
fidelity in the quality of data collection, a cross-site study protocol
was developed, and regular meetings were conducted to address
any concerns with data collection. Using multiple coders can lead to
Table 3. Distribution of codes by participants’ history of hydroxyurea use
Any hydroxyurea history* No hydroxyurea history†
Total coded by
nonadherence type
No. of patients No. of times coded % No. of patients No. of times coded % No. of times coded %
Total 78 12
Intentional nonadherence 25 30.1 7 38.8 32 31.1
Unintentional nonadherence 58 69.9 11 31.1 69 67.9
Total codes 83 82.2 18 17.8 101 100
*Five individuals endorsed both intentional and unintentional nonadherence barriers.
†One participant endorsed intentional and unintentional nonadherence barriers.
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misapplication of codes; however, duplicate coding and coding
meetings twice per month were used to address this concern. The
frequency of codes and themes may not necessarily represent the
importance of barriers in each individual’s decision-making process.
Finally, data were limited to what was provided by participants
based on their personal experiences.
In conclusion, in a study of 90 individuals with SCD at multiple
institutions across the United States, the role of patient agency in
adherence behaviors was introduced, and barriers leading to intentional
and unintentional adherence challenges for patients who are consid-
ering starting hydroxyurea therapy, those already receiving hydroxyurea
therapy, and those who have discontinued hydroxyurea therapy are
illustrated. Our results showed that unintentional adherence barriers
were reported with greater frequency, pointing to the importance of
recognizing these categories of barriers. Adherence is challenging to
address, and a greater understanding of complex barriers to adherence
can inform strategies in the clinical and research settings for overcoming
barriers.
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Table 4. Suggestions for interventions by adherence category
Components of adherence
Strategies for addressing nonadherence
Intentional Unintentional
Initiation Decides not to start • Open provider-patient discussions about potential
adverse effects of hydroxyurea, history, efficacy, and
pros and cons compared with other treatments,
including discussions about the potential effects of
having untreated SCD.
• Educate non-hematologists about hydroxyurea
indications for SCD.
• Have informal Q & A sessions with peers who are
currently taking hydroxyurea.
• Open provider-caregiver discussions about
hydroxyurea’s benefits, risks, and limitations and how
these will be monitored while receiving treatment.
• Explore personal concerns and beliefs to help alleviate
general aversion or fear of medication.
• For pediatric patients whose caregivers are
considering hydroxyurea, hold informal Q & A
sessions with other caregivers who opted to have
their child take hydroxyurea.
• Respect the final decision of the individual and be
open to future discussions.
Implementation Adherence while taking • Involve patient in reviewing laboratory results and
changes to results as they start taking hydroxyurea.
• Provide tools to help prompt individuals when to take
their medication (eg, phone app, incorporation into
daily routine).
• Continue open and ongoing provider-patient
conversations about concerns, worries, or perceived
effects resulting from taking hydroxyurea.
• Open provider-patient/caregiver discussions about
adherence challenges and potential strategies to
addressing barriers. Use strength- based approaches
to build on patient’s strengths to overcome
adherence challenges.
• Collaborate with patients to identify ways to address
barriers as they arise; use strength-based
approaches to build on patient’s strengths to
overcome adherence challenges.
• Continue routine discussions about any experienced
adverse effects or concerns about the impact of
taking hydroxyurea on the patient.
• Acknowledge and respect the challenges in
maintaining a daily medication regimen.
Discontinuation Decision to discontinue taking • Have open discussion with patient/caregiver on
factors leading to this decision.
• Have open discussion with patients and caregivers on
factors leading to this decision and what it means for
future opportunities and treatment modalities.
• Provide options for patients to continue hydroxyurea in
the future.
• Respect the final decision of the individual and be
open to future discussions.

















L user on 27 O
ctober 2020
Conflict-of-interest disclosure: J.S.H. received research support
from Global Blood Therapeutics (GBT) and Novartis and consultant
fees from GBT, UpToDate, and MJ Lifesciences. M.T. received
consultant fees from GBT. The remaining authors declare no
competing financial interests.
The current affiliation for S.N. is Walgreens Corporation,
Deerfield, IL.
ORCID profiles: J.R.H., 0000-0002-7418-6632; C.N., 0000-
0003-1079-7829; H.K., 0000-0002-7296-9684; A.K., 0000-0002-
1951-6176; M.T., 0000-0003-0521-1846; C.C., 0000-0002-
4997-1532; J.S.H., 0000-0003-4439-7321; J.P., 0000-0003-
0173-6522.
Correspondence: Jason R. Hodges, Department of Hematology,
St. Jude Children’s Research Hospital, 262 Danny Thomas Pl, MS
800, Memphis, TN 38105; e-mail: jason.hodges@stjude.org.
References
1. Alrayyes S, Baghdan D, Haddad RY, et al. Sickle cell disease: an overview of the disease and its systemic effects. Dis Mon. 2018;64(6):283-289.
2. Piel FB, Williams TN. Sickle cell anemia: History and epidemiology. Sickle Cell Anemia: From Basic Science to Clinical Practice. New York, NY: Springer
International Publishing; 2016:23-48.
3. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 suppl):S512-S521.
4. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of
treatment. JAMA. 2003;289(13):1645-1651.
5. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood
Cancer. 2012;59(2):365-371.
6. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle
cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354-2363.
7. Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr
Hematol Oncol. 2011;33(4):251-254.
8. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010;
85(8):611-613.
9. Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.
Expert Rev Hematol. 2010;3(3):255-260.
10. Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices:
a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79(2):107-113.
11. Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees
with sickle cell disease. Am J Hematol. 2011;86(3):273-277.
12. Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr
Hematol Oncol. 2018;35(5-6):297-308.
13. Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Adherence to hydroxyurea, health-related quality of life domains, and patients’
perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017;15(1):
136.
14. Loiselle K, Lee JL, Szulczewski L, Drake S, Crosby LE, Pai ALH. Systematic and meta-analytic review: Medication adherence among pediatric patients
with sickle cell disease. J Pediatr Psychol. 2016;41(4):406-418.
15. Baumann AA, Belle SH, James A, King AA; Sickle Cell Disease Implementation Consortium. Specifying sickle cell disease interventions: a study protocol
of the Sickle Cell Disease Implementation Consortium (SCDIC). BMC Health Serv Res. 2018;18(1):500.
16. Lehane E, McCarthy G. Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A
discussion paper. Int J Nurs Stud. 2007;44(8):1468-1477.
17. Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;
39(7-8):1198-1203.
18. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of
the Necessity-Concerns Framework. J Psychosom Res. 2008;64(1):41-46.
19. Molloy GJ, Messerli-Bürgy N, Hutton G, Wikman A, Perkins-Porras L, Steptoe A. Intentional and unintentional non-adherence to medications following an
acute coronary syndrome: a longitudinal study. J Psychosom Res. 2014;76(5):430-432.
20. Mentz RJ, Greiner MA, Muntner P, et al. Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart
Study. Am Heart J. 2018;200:51-59.
21. de Vries ST, Keers JC, Visser R, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2
diabetes. J Psychosom Res. 2014;76(2):134-138.
22. Rees G, Leong O, Crowston JG, Lamoureux EL. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma.
Ophthalmology. 2010;117(5):903-908.
23. Rebafka A. Medication adherence after renal transplantation-a review of the literature. J Ren Care. 2016;42(4):239-256.

















L user on 27 O
ctober 2020
24. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res.
2012;12(1):98.
25. Henning O, Johannessen Landmark C, Nakken KO, Lossius MI. Nonadherence to treatment regimens in epilepsy from the patient’s perspective and
predisposing factors: Differences between intentional and unintentional lack of adherence. Epilepsia. 2019;60(5):e58-e62.
26. Summers C, Curtis K. Novel digital architecture of a “low carb program” for initiating and maintaining long-term sustainable health-promoting behavior
change in patients with type 2 diabetes. JMIR Diabetes. 2020;5(1):e15030.
27. Ehrler F, Gschwind L, Meyer P, Christian L, Blondon K. SMART-MEDS: Development of a medication adherence app for acute coronary syndrome
patients based on a gamified behaviour change model. AMIA Annu Symp Proc. 2018;2018:413-421.
28. Santo K, Chow CK, Thiagalingam A, Rogers K, Chalmers J, Redfern J. MEDication reminder APPs to improve medication adherence in Coronary Heart
Disease (MedApp-CHD) Study: a randomised controlled trial protocol. BMJ Open. 2017;7(10):e017540.
29. Levy AE, Huang C, Huang A, Michael Ho P. Recent approaches to improve medication adherence in patients with coronary heart disease: Progress
towards a learning healthcare system. Curr Atheroscler Rep. 2018;20(1):5.
30. Mathes T, Großpietsch K, Neugebauer EAM, Pieper D. Interventions to increase adherence in patients taking immunosuppressive drugs after kidney
transplantation: a systematic review of controlled trials. Syst Rev. 2017;6(1):236.
31. Stevens EM, Patterson CA, Li YB, Smith-Whitley K, Barakat LP. Mistrust of pediatric sickle cell disease clinical trials research. Am J Prev Med. 2016;
51(1 suppl 1):S78-S86.
32. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005;61(1):133-155.
33. Perry EL, Carter PA, Becker HA, Garcia AA, Mackert M, Johnson KE. Health literacy in adolescents with sickle cell disease. J Pediatr Nurs 2017;36:
191-196.
34. Badawy SM, Thompson AA, Liem RI. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther. 2018;11(3):142-148.
35. Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood
Cancer. 2013;60(4):653-658.
36. DiMartino LD, Baumann AA, Hsu LL, et al; Sickle Cell Disease Implementation Consortium. The sickle cell disease implementation consortium:
Translating evidence-based guidelines into practice for sickle cell disease. Am J Hematol. 2018;93(12):E391-E395.
37. Mills J, Bonner A, Francis K. The Development of Constructivist Grounded Theory. Int J Qual Methods. 2006;5(1):25-35.
38. Charmaz K. Constructing Grounded Theory. 2nd ed. Thousand Oaks, CA: Sage; 2014.
39. Vrijens B, De Geest S, Hughes DA, et al; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin
Pharmacol. 2012;73(5):691-705.
40. Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91(2):238-242.
41. Haywood C Jr., Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell
disease. Am J Hematol. 2011;86(1):85-87.
42. Lanzkron S, Haywood C Jr., Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease
Adult Provider Network. J Natl Med Assoc. 2008;100(8):968-973.
43. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-5311.
44. Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical
outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.
45. Modi AC, Crosby LE, Guilfoyle SM, Lemanek KL, Witherspoon D, Mitchell MJ. Barriers to treatment adherence for pediatric patients with sickle cell
disease and their families. Child Health Care. 2009;38(2):107-122.
46. Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics.
2014;134(6):1175-1183.
47. Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults
with sickle cell disease. Pediatr Blood Cancer. 2016;63(5):848-852.
48. Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and
young adults with sickle cell disease. Eur J Haematol. 2017;98(6):608-614.
49. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415-419.
50. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for
sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
51. Inoue S, Kodjebacheva G, Scherrer T, et al. Adherence to hydroxyurea mediation by children with sickle cell disease (SCD) using an electronic device: A
feasibility study. Int J Hematol. 2016;104(2):200-207.
52. Creary SE, Gladwin MT, Byrne M, HildesheimM, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in
pediatric patients with sickle-cell disease. Pediatr Blood Cancer. 2014;61(6):1068-1073.
53. Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with
sickle cell anemia. Pediatr Blood Cancer. 2014;61(11):2031-2036.
54. Green NS, Manwani D, Matos S, et al. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health
workers: The HABIT study. Pediatr Blood Cancer. 2017;64(12):e26689.

















L user on 27 O
ctober 2020
55. Alberts NM, Badawy SM, Hodges J, et al. Development of the InCharge Health Mobile App to improve adherence to hydroxyurea in patients with sickle
cell disease: User-centered design approach. JMIR Mhealth Uhealth. 2020;8(5):e14884.
56. Hankins JS, Shah N, DiMartino L, et al; Sickle Cell Disease Implementation Consortium. Integration of mobile health into sickle cell disease care to
increase hydroxyurea utilization: Protocol for an efficacy and implementation study. JMIR Res Protoc. 2020;9(7):e16319.
57. Knisely MR, Pugh N, Kroner B, et al; Sickle Cell Disease Implementation Consortium. Patient-reported outcomes in sickle cell disease and association
with clinical and psychosocial factors: report from the sickle cell disease implementation consortium [published online ahead of print 25 May 2020].
Am J Hematol. doi:10.1002/ajh.25880.

















L user on 27 O
ctober 2020
